CD99 is a novel prognostic stromal marker in non-small cell lung cancer

International Journal of Cancer

Volumn 131, Issue 10, 2012, Pages 2264-2273

  Edlund, Karolina ^a   Lindskog, Cecilia ^a   Saito, Akira ^b   Berglund, Anders ^c   Pontén, Fredrik ^a   Göransson Kultima, Hanna ^a   Isaksson, Anders ^a   Jirström, Karin ^d   Planck, Maria ^d   Johansson, Leif ^d   Lambe, Mats ^c   Holmberg, Lars ^c,e   Nyberg, Fredrik ^b,f,g   Ekman, Simon ^a   Bergqvist, Michael ^a   Landelius, Per ^c   Lamberg, Kristina ^c   Botling, Johan ^a   Östman, Arne ^b   Micke, Patrick ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

CAF; CD99; gene expression; lung cancer; tissue microarray; tumour stroma

Indexed keywords

BIGLYCAN; CD99 ANTIGEN; DECORIN; ELASTIN; ELASTIN MICROFIBRIL INTERFACE LOCATED PROTEIN 1; FIBRILLIN 1; LIM PROTEIN; LIM5 PROTEIN; OSTEONECTIN; PDZ PROTEIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TENASCIN; TRANSCRIPTION FACTOR RUNX2; TRANSGELIN; TUMOR MARKER; UNCLASSIFIED DRUG; VERSICAN;

AGED; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER PATIENT; CANCER PROGNOSIS; CANCER SCREENING; CELL DIFFERENTIATION; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE SEQUENCE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY CELL; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; TUMOR GROWTH; UNIVARIATE ANALYSIS;

ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION MOLECULES; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; PROGNOSIS; PROTEIN TRANSPORT; PROTEOME; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84867063079     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27518     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, Gasparini P, Perrone F, Modena P, Pastorino U, Carbone A, Fabbri A, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumour lung tissues. Am J Pathol 2009; 174: 661-70.
3. Shigematsu H, Gazdar AF,. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118: 257-62.
4. Micke P, Östman A,. Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 2005; 9: 1217-33.
5. De Wever O, Demetter P, Mareel M, Bracke M,. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008; 123: 2229-38.
6. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M,. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518-27.
7. Bergamaschi A, Tagliabue E, Sørlie T, Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Ménard S, et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 2008; 214: 357-67.
8. Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, Stephens RM, Yfantis HG, Lee DH, Weinstein JN, Ambs S,. A stromal gene signature associated with inflammatory breast cancer. Int J Cancer 2008; 122: 1324-32.
9. Pontén F, Schwenk JM, Asplund A, Edqvist PH,. The Human Protein Atlas as a proteomic resource for biomarker discovery. J Intern Med 2011; 270: 428-46.
10. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Björling L, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010; 28: 1248-50.
11. Mikula M, Rubel T, Karczmarski J, Goryca K, Dadlez M, Ostrowski J,. Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumours. Funct Integr Genomics 2011 (Epub ahead of print).
12. Lee JH, Kim SH, Wang LH, Choi YL, Kim YC, Kim JH, Park TS, Hong YC, Shin YK,. Clinical significance of CD99 down-regulation in gastric adenocarcinoma. Clin Cancer Res 2007; 13: 2584-91.
13. Manara MC, Bernard G, Lollini PL, Nanni P, Zuntini M, Landuzzi L, Benini S, Lattanzi G, Sciandra M, Serra M, Colombo MP, Bernard A, et al. CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell 2006; 17: 1910-21.
14. Goldoni S, Iozzo RV,. Tumour microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 2008; 123: 2473-9.
15. Augoff K, Grabowski K, Rabczynski J, Kolondra A, Tabola R, Sikorski AF,. Expression of decorin in esophageal cancer in relation to the expression of three isoforms of transforming growth factor-β (TGF-β1, -β2, and -β3) and matrix metalloproteinase-2 activity. Cancer Invest 2009; 27: 443-52.
16. Spessotto P, Bulla R, Danussi C, Radillo O, Cervi M, Monami G, Bossi F, Tedesco F, Doliana R, Colombatti A,. EMILIN1 represents a major stromal element determining human trophoblast invasion of the uterine wall. J Cell Sci 2006; 119: 4574-84.
17. Summers KM, Bokil NJ, Baisden JM, West MJ, Sweet MJ, Raggatt LJ, Hume DA,. Experimental and bioinformatic characterisation of the promoter region of the Marfan syndrome gene, FBN1. Genomics 2009; 94: 233-40.
18. Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I, Busund LT,. The role of tumour stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 2011; 6: 209-17.
19. Ruan K, Bao S, Ouyang G,. The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci 2009; 66: 2219-30.
20. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G,. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 2008; 14: 7430-7.
21. Chlenski A, Cohn SL,. Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol 2010; 21: 55-65.
22. Rho JH, Roehrl MH, Wang JY,. Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. J Proteome Res 2009; 8: 5610-18.
23. Orend G, Chiquet-Ehrismann R,. Tenascin-C induced signaling in cancer. Cancer Lett 2006; 244: 143-63.
24. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ,. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 2009; 28: 233-45.
25. Micke P, Edlund K, Holmberg L, Göransson H, Ekman S, Bergqvist M, Scheibenflug L, Lamberg K, Myrdal G, Berglund A, Lambe M, Nyberg F, et al. Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer. J Thorac Oncol 2011; 6: 1833-40.
26. Nocito A, Kononen J, Kallioniemi OP, Sauter G,. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001; 94: 1-5.
27. Segersten MU, Edlund EK, Micke P, de la Torre M, Hamberg H, Edvinsson AE, Andersson SE, Malmström PU, Wester HK,. A novel strategy based on histological protein profiling in-silico for identifying potential biomarkers in urinary bladder cancer. BJU Int 2009; 104: 1780-5.
28. Saito RA, Micke P, Paulsson J, Augsten M, Peña C, Jönsson P, Botling J, Edlund K, Johansson L, Carlsson P, Jirström K, Miyazono K, et al. Forkhead box F1 regulates tumour-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Res 2010; 70: 2644-54.
29. Levy R, Dilley J, Fox RI, Warnke R,. A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies. Proc Natl Acad Sci USA 1979; 76: 6552-6.
30. Petit C, Levilliers J, Weissenbach J,. Physical mapping of the human pseudo-autosomal region; comparison with genetic linkage map. EMBO J 1988; 7: 2369-76.
31. Alberti I, Bernard G, Rouquette-Jazdanian AK, Pelassy C, Pourtein M, Aussel C,. CD99 isoforms expression dictates T cell functional outcomes. FASEB J 2002; 16: 1946-8.
32. Scotlandi K, Zuntini M, Manara MC, Sciandra M, Rocchi A, Benini S, Nicoletti G, Bernard G, Nanni P, Lollini PL, Bernard A, Picci P,. CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene 2007; 26: 6604-18.
33. Gelin C, Aubrit F, Phalipon A, Raynal B, Cole S, Kaczorek M, Bernard A,. The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product. EMBO J 1989; 8: 3253-9.
34. Dworzak MN, Fritsch G, Buchinger P, Fleischer C, Printz D, Zellner A, Schöllhammer A, Steiner G, Ambros PF, Gadner H,. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood 1994; 83: 415-25.
35. Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M,. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumours. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumours from MIC2 expression and specific chromosome aberration. Cancer 1991; 67: 1886-93.
36. Buxton D, Bacchi CE, Gualco G, Weiss LM, Zuppan CW, Rowsell EH, Huang Q, Wang J,. Frequent expression of CD99 in anaplastic large cell lymphoma: a clinicopathologic and immunohistochemical study of 160 cases. Am J Clin Pathol 2009; 13: 574-9.
37. Hartel PH, Fanburg-Smith JC, Frazier AA, Galvin JR, Lichy JH, Shilo K, Franks TJ,. Primary pulmonary and mediastinal synovial sarcoma: a clinicopathologic study of 60 cases and comparison with five prior series. Mod Pathol 2007; 20: 760-9.
38. Lee JC, Fletcher CD,. Malignant fat-forming solitary fibrous tumour (so-called "Lipomatous Hemangiopericytoma"): clinicopathologic analysis of 14 cases. Am J Surg Pathol 2011; 35: 1177-85.
39. Choi YL, Kim HS, Ahn G,. Immunoexpression of inhibin alpha subunit, inhibin/activin β A subunit and CD9 in ovarian tumours. Arch Pathol Lab Med 2000; 124: 563-9.
40. Gordon MD, Corless C, Renshaw AA, Beckstead J,. CD99, keratin, and vimentin staining of sex cord-stromal tumours, normal ovary, and testis. Mod Pathol 1998; 11: 769-73.
41. Milanezi F, Pereira EM, Ferreira FV, Leitão D, Schmitt FC,. CD99/MIC-2 surface protein expression in breast carcinomas. Histopathology 2001; 39: 578-83.
42. Goto A, Niki T, Terado Y, Fukushima J, Fukayama M,. Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs). Histopathology 2004; 45: 384-92.
43. Choi YL, Xuan YH, Shin YK, Chae SW, Kook MC, Sung RH, Youn SJ, Choi JW, Kim SH,. An immunohistochemical study of the expression of adhesion molecules in gallbladder lesions. J Histochem Cytochem 2004; 52: 591-601.
44. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, et al. Molecular characterisation of the tumour microenvironment in breast cancer. Cancer Cell 2004; 6: 17-32.
45. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès- Fridman C, Fridman WH,. Immune infiltration in human tumours: a prognostic factor that should not be ignored. Oncogene 2010; 29: 1093-102.
46. Ito N, Suzuki Y, Taniguchi Y, Ishiguro K, Nakamura H, Ohgi S,. Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Res 2005; 25: 2027-31.
47. Wilke CM, Wu K, Zhao E, Wang G, Zou W,. Prognostic significance of regulatory T cells in tumour. Int J Cancer 2010; 127: 748-58.
48. Micke P, Kappert K, Ohshima M, Sundquist C, Scheidl S, Lindahl P, Heldin CH, Botling J, Pontén F, Ostman A,. In situ identification of genes regulated specifically in fibroblasts of human basal cell carcinoma. J Invest Dermatol 2007; 127: 1516-23.
49. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, Ramnarine VR, Ibrahimov E, Radulovich N, Leung L, Barczyk M, Panchal D, To C, et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci USA 2011; 108: 7160-5.
50. Coussens LM, Fingleton B, Matrisian LM,. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-92.